Rapidai Inc. landed $75 million in a series C financing led by Vista Credit Partners. The funds will be used to fuel development of additional indications and expand market reach of its artificial intelligence (AI)-powered clinical decisionmaking and workflow support technology. With this latest round, the San Mateo, Calif.-based company has raised approximately $100 million, according to Crunchbase.

Deep learning algorithms are used to remotely monitor and track just about everything these days and now that includes ordinary and chronic cough. Hyfe Inc. has launched an AI-driven remote patient monitoring (RPM) program designed to monitor cough for a whole range of serious ailments at virtual hospitals, remote care and telehealth programs across the U.S.

Medical device company Know Labs Inc. reported results from a new study showing that continued algorithm refinement combined with more high-quality data significantly increased the accuracy of its Body-Radio Frequency Identification, or Bio-RFID, sensor technology to measure and detect changes in blood glucose levels.

ArteraAI Inc. released data from a study it said validates the first-ever artificial intelligence (AI)-derived biomarker predicting the benefit of androgen deprivation therapy (ADT) for stripping prostate cancer of the testosterone it requires to grow.

Neko Health AB reported it has secured $67 million in investment capital to develop its artificial intelligence (AI)-driven full body scanner beyond its home country, Sweden. This series A round was led by Berlin-based Lakestar Advisors GmbH, with participation from Atomico (UK) Partners LLP from London and General Catalyst Group Management LLC from Cambridge, Mass. “Our new concept in body digitization technology, capable of rapidly collecting large amounts of health data, will enable us to identify illness at an early stage and take preventive action,” Hjalmar Nilsonne, CEO and co-founder of Neko Health told BioWorld.

Sonio SAS closed its series A fundraising round raising $14 million that will go some way in helping the company deliver on its mission to improve access to quality pregnancy monitoring for women everywhere through its software-as-a-service (SaaS) platform. Sonio has developed an artificial intelligence (AI) prenatal screening solution that automates ultrasound reporting while providing image quality control and detection of potential anomalies. The capital raise was led by Cross-Border Impact Ventures, a North American impact fund dedicated to the health of women and children.

Device makers are often cited in U.S. FDA warning letters for making claims not seen in the approved labeling, but the authors of a recent review of artificial intelligence (AI) products cleared by the FDA suggest that FDA documents and marketing materials should disclose the presence of AI in these products. The authors of an article in the Journal of the American Medical Association said that only about 80.6% of the products were represented with accurate statements about the presence of AI, although FDA regulation does not require that marketing materials make such disclosures.